Oramed Pharma

Q2 FY2026 EarningsQ2 FY26 results significantly exceeded consensus estimates, primarily driven by massive non-cash valuation gains from strategic investments. GAAP Net Income reached $78.16M compared to the $17.90M consensus, while Diluted EPS of $1.84 far outperformed the $0.43 estimate. Following the Lifeward transaction and transfer of POD™ technology, the company has successfully transitioned into a strategic holding entity, with its investment in Alpha Tau contributing $96.99M in unrealized gains during the quarter.